SPO Medical : Innovative Wellness Bracelet

May 25 2010 - SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced that it has designed a unique bracelet to measure the overall daily activity level of an individual and specifically for use by those who are deemed to be overweight or obese. The bracelet, designed both for children and adults, has innovative features including display functionality and a time-piece which continuously measures number of daily movements against preset recommended goals. Furthermore, the attractive wrist design is designed to encourage these individuals to wear the bracelet with pride.
According to independent reports, approximately 100 million adults and children today in the US are considered to be obese; a condition defined as having a Body Mass Index (BMI) in excess of 30. In addition, obesity is known to be a major factor for cardiovascular disease, diabetes and certain types of cancer... [PDF] SPO Medical's Press Release -

Aegis Therapeutics and Albany Medical : Collaboration for Novel Oral Anti-Obesity Drug

August 26, 2009 – Aegis Therapeutics and Albany Medical College announced that they have expanded their existing research relationship, entering into a joint commercialization agreement to promote the clinical development of Albany Medical College’s patented anti-obesity peptide drug. Under this agreement, Aegis will be responsible for developing an appropriate partnership with a pharmaceutical company interested in commercializing this exciting new drug in the obesity and diabetes fields... [PDF]Aegis Therapeutics' Press Release -

Spatz FGIA : First Implants of Spatz (TM) Adjustable Intragastric Balloon System

October 19, 2009 - Spatz FGIA, Inc., a privately held medical device company, announced the first implants of its Spatz (TM) Adjustable Balloon System. The Spatz (TM) Adjustable Balloon System is a non-surgical weight loss therapy for the overweight and obese. The system’s innovative features offer greater weight-loss success, increased patient safety, and ease of use for the physician... Spatz FGIA's Press Release -

PROLOR Biotech : LICENSE OPTION FROM YEDA FOR DEVELOPMENT OF LONG-ACTING ANTI-OBESITY DRUG

July 27, 2009 -- PROLOR Biotech, Inc. (OTCBB: PBTH) formerly Modigene Inc., announced that it has entered into an evaluation and option agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science. Under the terms of the evaluation and option agreement, PROLOR may obtain from Yeda a license to develop a number of peptide drug candidates, including an anti obesity peptide, utilizing a delivery technology developed at the Weizmann Institute. The Weizmann Institute of Science is a world-renowned center of natural and exact sciences research and higher learning based in Rehovot, Israel... [PDF] PROLOR Biotech's Press Release -

Mylan Pharmaceuticals : Marketing First Generic Version of Desoxyn(R)

April 26, 2010 - Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market Methamphetamine Hydrochloride Tablets USP, 5 mg, based on an agreement with licensing partner Coastal Pharmaceuticals. This product, used for the treatment of attention deficit hyperactivity disorder or obesity, is the first generic version of Lundbeck's Desoxyn(R) to be approved by the U.S. Food and Drug Administration (FDA)... Mylan' Press Release -